References
- Wang JC. DNA Topoisomerases. Ann Rev Biochem 1996; 65: 635–692
- Ting CY, Hsu CT, Hsu HT, Su JS, Chen TY, Tarn WY, Kuo YH, Jacqueline WP, Liu LF, Hwang J. Isodiospyrin as a novel human DNA topoisomerase I Inhibitor. Biochem Pharm 2003; 66: 1981–1991
- Nitiss JL. Investigating the biological function of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 1998; 1400: 63–81
- Seaton A, Higgins C, Mann J, Baron A, Bailly C, Neidle S, Van Den Berg H. Mechanistic and anti-proliferate studies of two novel, biologically active bis-Benzimidazoles. Eur J Cancer 2003; 39: 2548–2555
- Bodley AL, Liu LF. Topoisomerases as novel targets for cancer chemotherapy. Biotechnology 1988; 6: 1315–1318
- Schneider E, Hsiang YH, Liu LF. DNA topoisomerase as anticancer drug targets. Adv Pharmacol 1990; 21: 149–183
- Chen AY, Liu LF. DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191–218
- Gallo RC, Whan-Peng J, Adamson RAH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 1971; 46: 789–795
- Alper S, Temiz-Arpaci O, Aki-Sener E, Yalcin I. Some new bi- and terbenzimidazole derivatives as topoisomerase I inhibitors. Il Farmaco 2003; 58: 497–507
- Tolner B, Hartley JA, Hochhauser D. Transcriptal regulation of topoisomerase IIa at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol Pharmacol 2001; 59: 699–706
- Sun Q, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. J Med Chem 1995; 38: 3638–3644
- Finlay GJ, Baguley BC. Potentiation by phenylbisbenzimidazoiles of cytotoxicity of anticancer drugs directed against topoisomerase II. Eur J Cancer 1990; 26: 586–589
- Rowe TC, Chen GL, Hsiang YH, Liu F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986; 46: 2021–2026
- Peel MR, Milstead MW, Sternbach DD, Besterman M, Leitner P, Morton B. Novel A-ring modified camptothecins as topoisomerase I inhibitors. Bioorg Med Chem Lett 1995; 5: 2129–2132
- Pinar A, Yurdakul P, Yildiz I, Temiz-Arpaci O, Acan NL, Aki-Sener E, Yalcin I. Some fused heterocyclic compounds as eukaryotic topoisomerase II Inhibitors. Biochem Biophys Res Comm 2004; 317: 670–674
- Temiz-Arpaci O, Tekiner-Gulbas B, Yildiz I, Aki-Sener E, Yalcin I. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method. Bioorg Med Chem 2005; 13: 6354–6359
- Tekiner-Gulbas B, Temiz-Arpaci O, Yildiz I, Aki-Sener E, Yalcin I. 3D-QSAR study on heterocyclic topoisomerase II inhibitors using CoMSIA. SAR QSAR Environ Res 2006; 17: 121–132
- Yalcin I, Sener E. QSARs of some novel antibacterial benzimidazoles, benzoxazoles and oxazolopyridines against an enteric gram-negative rod; K. pneumoniae. Int J Pharmaceutics 1993; 98: 1–8
- Yalcin I, Oren I, Sener E, Akin A, Ucarturk N. The synthesis and the structure-activity relationships of some substituted benzoxazoles, oxazolo(4,5-b)pyridines, benzothiazoles and benzimidazoles as antimicrobial agents. Eur J Med Chem 1992; 27: 401–406
- Yildiz IO, Yalcin I, Aki ES, Ucarturk N. Synthesis and structure-activity relationships of new antimicrobial active multisubstituted benzazole derivatives. Eur J Med Chem 2004; 39: 291–298
- Osheroff N, Shelton ER, Brutlag D. DNA topoisomerase II from drosophila melanogaster, relaxation of supercoiled DNA. J Biol Chem 1983; 258: 9536–9543
- Barrett JF, Sutcliffe JA, Gootz TD. In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother 1990; 34: 1–7